Skip to main content

Table 1 Patient demographics

From: Efficacy of radioactive iodine treatment of graves’ hyperthyroidism using a single calculated 131I dose

Characteristics Number of patients (%)
Age 42.1 ± 16 y, 4–94a
 Pediatric pts. < 18 y 20 (6.3)
 Adult pts. ≥ 18 y 296 (93.7)
 Total 316
Gender
 Female 238 (75.3)
 Male 78 (24.6)
Etiology of hyperthyroidism
 Graves’ disease 316 (100%)
History of prior treatment
 None 179 (56.6)
 Anti-thyroid medications
  Propylthiouracil 80 (25.3)
  Methimazole 37 (11.7)
  Both (PTU and MMI) 14 (4.4)
  Total 137 (43.4)
 Surgery
  Yes 6 (1.9)
Interval between diagnosis and radioiodine treatment 325.9 d, 0–6818
Radioiodine treatment
 Size of gland (g) 50.2 ± 18.1, 15–100a
 24-h RAIU 0.57 ± 0.17
131I dose administered (mCi) 18.1 ± 6.8, 5–70a
 Dosing factor (mCi per gram) 0.21 ± 0.14
Outcomes at First RAI Therapy 316
 Success 295 (93.3)
 Failure 21 (6.6)
  Failure (needed 2 RAI doses) 18 (5.7)
  Failure (needed thyroidectomy) 1 (< 0.3)
  Failure (needed 3 RAI doses) 2 (< 0.7)
Interval between radioiodine treatment and hypothyroidism 97.3 d ± 78.4
  1. apresented as mean ± SD, range